Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

FRNMBullishIndustry Newsnews

High materiality7/10

Freenome launches SimpleScreen Lung enabling single-draw multi-cancer screening

Oct 20, 2026, 9:04 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive validation and a meaningful new offering may lift FRNM's stock on reduced execution risk and expanded TAM; valuation impact hinges on adoption pace and reimbursement.

AI summary

What happened, with direct paths to the underlying reporting

Freenome unveiled SimpleScreen Lung, a blood-based test that can screen for both lung and colorectal cancer from a single draw. Independent cohort data show 85% sensitivity at 50% specificity and a 99.8% negative predictive value for lung cancer, suggesting strong near-term diagnostic value and potential for expanded addressable market and early adoption.

Freenome launches SimpleScreen Lung; enables single-blood-draw multi-cancer screening.
Independent data show 85% sensitivity, 50% specificity, 99.8% NPV for lung cancer.
First-of-its-kind offering screens lung and colorectal cancer via one draw.
News release from Brisbane, CA; Freenome (Nasdaq: FRNM) on Oct. 20, 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Freenome launches SimpleScreen Lung enabling single-draw multi-cancer screening

FDA approval clears Freenome test as Abbott prepares U.S. launch